scholarly journals B-TYPE NATRIURETIC PEPTIDE(BNP) LEVELS AND ITS PROGNOSTIC VALUE IN ACUTE CORONARY SYNDROMES(ACS)

2020 ◽  
pp. 27-29
Author(s):  
Rajinder Kumar ◽  
Muzaffar Majeed Khujwal ◽  
Isha Sharma ◽  
Niyaz Ahmad

Objectives: This study was designed to evaluate the prognostic value of B-type natriuretic peptide (BNP) in patients across the entire spectrum of acute coronary syndromes (ACS). Method: We measured BNP levels at baseline in 100 consecutive patients between 24-96 hours after the onset of ischemic symptoms in patients of acute coronary syndromes. We did comparison between BNP levels and established prognostic markers Trop-T to determine short term morbidity and mortality. Results: Patients with baseline BNP levels (> 80pg/ml, n=28) were at higher risk of new or progressive congestive heart failure (CHF) [17.8% vs. 1.39%, P = 0.002), new or recurrent myocardial infarction [17.8% vs. 2.8, P = 0.008) and death [17.8% vs. 1.39%, P= 0.002) within a period of 30 days. The mortality within 30 days in patients with BNP > 80pg/ml was 17.9% (P=0.002)compared to 5.7%(P=0.718) in patients with positive Trop-T (> 0.1ng/ml). Conclusion: A single measurement of BNP obtained between 24-96 hours after the onset of ischemic symptoms provides predictive information for use in risk stratifications across the spectrum of acute coronary syndromes. Cardiac neurohormonal activation may be a unifying feature among patients at high risk for death after acute coronary syndromes. BNP levels should be measured in all patients of Acute coronary syndromes.

Circulation ◽  
2004 ◽  
Vol 110 (2) ◽  
pp. 128-134 ◽  
Author(s):  
Marcello Galvani ◽  
Filippo Ottani ◽  
Luigi Oltrona ◽  
Diego Ardissino ◽  
Gian Franco Gensini ◽  
...  

2001 ◽  
Vol 345 (14) ◽  
pp. 1014-1021 ◽  
Author(s):  
James A. de Lemos ◽  
David A. Morrow ◽  
Jane H. Bentley ◽  
Torbjørn Omland ◽  
Marc S. Sabatine ◽  
...  

1970 ◽  
Vol 110 (4) ◽  
pp. 77-80
Author(s):  
M. R. Babarskiene ◽  
J. Vencloviene ◽  
D. Luksiene ◽  
I. Milvidaite

Ischemic heart disease is the leading cause of death in Europe among males over 45 years of age and females older than 65. The aim of the study: to evaluate the informative value of the models in ACS patients using GRACE (GR) risk score, to identify additional informative indicators for short-term and long-term prognosis following ACS, and to evaluate the prognostic reliability of the integrated model. The study included 1491 patients who in 2005 were treated for ACS in the Department of Cardiology, the Hospital of Kaunas University of Medicine. We devised an adjusted prognostic index for making short and long-term prognosis in patients with acute coronary syndromes (STEMI and NSETMI). Following adjustment of the GR scores, the prognostic value improved for STEMI patients. Ill. 2, bibl. 12, tabl. 3 (in English; abstracts in English and Lithuanian).http://dx.doi.org/10.5755/j01.eee.110.4.292


2021 ◽  
Vol 10 (Supplement_1) ◽  
Author(s):  
I Almeida ◽  
H Miranda ◽  
H Santos ◽  
M Santos ◽  
J Chin ◽  
...  

Abstract Funding Acknowledgements Type of funding sources: None. OnBehalf Portuguese Registry of Acute Coronary Syndromes (ProACS) Introduction Brain natriuretic peptide (BNP) is a highly sensitive and specific biomarker on the extension of myocardial infarction, strongly related to short and long-term prognosis in patients with ST elevation myocardial infarction (STEMI). Objective To evaluate diagnostic and prognostic value of BNP levels in a Portuguese cohort of STEMI patients. Material and methods Retrospective analysis of patients admitted with STEMI included in the Portuguese Registry of Acute Coronary Syndromes between 2010-19. Patients were divided in three groups regarding BNP: Group 1 if BNP <100 pg/ml; Group 2 100 ≤ BNP < 400 pg/ml and Group 3 ≥400 pg/ml. Independent predictors of a composite of all-cause mortality and rehospitalization for cardiovascular causes were assessed by multivariate logistic regression. Results 1650 patients were included, mean age 64 ± 13 years, 75.4% male. 39.0% (n = 643) integrated group 1, 39.5% (n = 652) group 2 and 21.5% (n = 355) group 3. Group 3 patients were significantly older (58 ± 11 vs 66 ± 13 vs 72 ± 12 years, p < 0.001), had more classic cardiovascular risk factors, except for smoker status, and more previous history of cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease and cancer. Anterior STEMI was the most frequent location (51.1%), however group 3 patients presented with lower systolic blood pressure (136 ± 30 vs 140 ± 31 vs 131 ± 28 mmHg, p < 0.001) and higher heart rate (76 ± 17 vs 77 ± 19 vs 84 ± 26 bpm, p < 0.001) and KK class (KK class > I 5.6 vs 9.5 vs 28.5%, p < 0.001). They also presented higher levels of creatinine (1 ± 0.5 vs 1.2 ± 0.9 vs 1.5 ± 1 mg/dl, p < 0.001) and the lowest levels of hemoglobin (13.5 ± 1.6 vs 12.6 ± 1.9 vs 11.7 ± 2.1 g/dl, p < 0.001). Mean ejection fraction (EF) was lower in group 3 (58 ± 11 vs 53 ± 12 vs 44 ± 13%, p < 0.001). Multivessel disease was more common in group 3 (34.8 vs 44.8 vs 51.3%, p < 0.001), where a higher percentage was proposed to medical therapy (2.8 vs 3.5 vs 8.5%, p < 0.001). In the patients proposed to revascularization, although not statistically significant, there was a trend towards surgical revascularization or hybrid approach. In-hospital complications were more frequent in group 3, especially heart failure (HF) (18.9% mean vs 45.4%, p < 0.001), and mortality was seven times superior in group 3 versus group 1 (1.2% vs. 8.5%, p < 0.001). The composite endpoint of 1-year mortality and cardiovascular rehospitalization occurred in 12%. After propensity score application, the 1-year endpoint total mortality rate and cardiovascular readmission was 20.3%, and higher BNP was associated with higher rates (p < 0.001). Predictor factors for the composite endpoint, evaluated through Cox multivariate regression were previous HF, multivessel disease, EF < 30% and the use of nitrates and aldosterone antagonists. The use of aspirin was a protector factor. Conclusion BNP levels during index hospitalization were a powerful prognostic biomarker for all-cause mortality MACE in patients admitted with STEMI.


2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P2248-P2248
Author(s):  
J. Mesquita ◽  
N. Cortez-Dias ◽  
P. Canas Da Silva ◽  
T. Pessoa ◽  
M. Fiuza ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document